Navigation Links
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Results

ROCKVILLE, Md., Feb. 10, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced financial and operational results for the fourth quarter and full year ended December 31, 2010.

"2010 has been an exceptional milestone year in the history of our company.  Our first product, Fanapt®, reached the U.S. market for the treatment of schizophrenia, we had our first profitable year and we have advanced our second asset, tasimelteon, in Phase 3 studies," said Mihael Polymeropoulos, M.D., President and Chief Executive Officer. "2011 will be a foundation year for Vanda, as we begin to execute upon our vision of building a world class neuroscience pharmaceutical company."

Key Highlights:

  • Vanda recorded 2010 revenue of $35.2 million including royalties and product sales of $8.4 million.  
  • Cash and cash equivalents plus marketable securities at year end 2010 were $198.0 million as compared to $205.3 million at year end 2009.
  • Monthly prescriptions of Fanapt®, as reported by IMS, increased from over 6,000 in September of 2010 to over 8,000 in December of 2010. For the full year 2010, more than 55,000 prescriptions have been written.
  • Tasimelteon efficacy and safety studies are ongoing in both the U.S. and Europe.
  • On November 15, 2010, Vanda received a private letter ruling (PLR) from the Internal Revenue Service (IRS) clarifying the company's ability to utilize net operating loss carryforwards for tax purposes.  

  • Full Year 2010 Reported ResultsTotal revenues for the full year 2010 were $35.2 million, compared to $4.5 million for the same period in 2009.  2010 revenues included $26.8 million recognized from the $200.0 million upfront payment previously received from Novartis for Fanapt® U.S. and Canadian rights.  Total operating expenses for 2010 were $26.9 million, compared to $40.5 million for 2009.  The lower 2010 spend is primarily related to decreased business development consulting fees and lower non-cash stock based compensation for the period.

    Net income was $7.2 million for 2010, compared to a net loss of $35.9 million for 2009.  Diluted earnings per share for 2010 was $0.25, compared to a net loss per share of $1.33 for 2009.  Vanda's cash, cash equivalents, and marketable securities as of December 31, 2010 totaled $198.0 million.

    Fourth Quarter 2010 Reported ResultsTotal revenues for the fourth quarter of 2010 were $7.3 million, compared to $4.5 million for the same period in 2009.  Fourth quarter 2010 revenues include $0.5 million related to Fanapt® royalties received from Novartis.  Total operating expenses for the fourth quarter of 2010 were $7.0 million, compared $13.8 million for the fourth quarter of 2009.  The primary drivers of the lower 2010 spend were the one time nature of Fanapt® product cost of goods sold in 2009 and the previously mentioned decrease in business development expenses.

    Net income was $2.2 million for the fourth quarter of 2010, compared to a net loss of $9.2 million for the fourth quarter of 2009.  Diluted earnings per share for the fourth quarter of 2010 was $0.08, compared a net loss per share of $0.34 for the fourth quarter of 2009. Full Year December 31, 2010 Key Financial Figures(1)Twelve Months EndedDecember 31December 31(in thousands, except per share amounts)

    20102009Change ($)Change (%)Total revenues

    30,672674%Research & development  expenses

    12,33813,874(1,536)-11%General & administrative expenses

    10,14723,724(13,577)-57%Non-cash stock-based compensation

    4,98111,230(6,249)-56%Net income (loss) before tax provision

    9,269(35,859)45,128126%Tax provision

    2,077-2,077NANet income (loss)  

    7,192(35,859)43,051120%Diluted net income (loss) per share

    .58119%Fourth Quarter 2010 Key Financial Figures(1)Three Months EndedDecember 31September 30(in thousands, except per share amounts)

    20102010Change ($)Change (%)Total revenues

    70%Research & development  expenses

    3,8224,072(250)-6%General & administrative expenses

    2,7622,05470834%Non-cash stock-based compensation

    1,33588744851%Net income before tax provision

    933899344%Tax benefit

    (1,266)(2,285)1,01945%Net income

    2,1993,184(985)-31%Diluted net income per share

    (0.03)-27%Select Balance Sheet Data(1)December 31September 30December 31(in thousands, except per share amounts)

    201020102009Total cash and marketable securities

    Unaudited OPERATIONAL HIGHLIGHTS   Full year 2010 sales of Fanapt® were reported by Novartis to be $31.4 million which included $5.1 million in the fourth quarter of 2010.  Vanda is encouraged by the continuing growth in the total number of monthly prescriptions, as reported by IMS. Fanapt® prescriptions continued to increase month-over-month during the fourth quarter of 2010. Monthly prescriptions of Fanapt®, as reported by IMS, increased from over 6,000 in September of 2010 to over 8,000 in December of 2010.  For the full year 2010, more than 55,000 prescriptions were written.

    We have been informed by our partner, Novartis, that a clinical study will be initiated in early 2011 for the once a month injectable depot formulation of iloperidone.  On October 28, 2010, the U.S. Patent and Trademark Office (USPTO) informed Vanda that it had granted an additional patent term adjustment for the depot formulation, making the patent expiration date August 25, 2023.

    Vanda continues to explore the regulatory path and commercial opportunity for the Fanapt® oral formulation outside of the U.S. and Canada.  On November 1, 2010, Australia's Department of Health and Ageing – Therapeutic Goods Administration, accepted for evaluation Vanda's application for marketing approval.

    Enrollment is ongoing in the tasimelteon Study VP-VEC-162-3201, a 160-patient randomized controlled trial of tasimelteon versus placebo in the treatment of Non-24-Hour Sleep/Wake Disorder (N24HSWD) in blind individuals with no light perception. The trial has a 6-month treatment period and includes measures of both nighttime and daytime sleep, as well as laboratory measures of the synchronization between the internal body clock and the 24-hour environmental light/dark cycle.

    Vanda has also initiated a one-year safety study of tasimelteon for the treatment of N24HSWD.  This is an open-label safety study that will enroll approximately 140 patients with N24HSWD.  Vanda plans to conduct additional clinical trials over the next one to two years to support U.S. and European regulatory submissions. Tasimelteon was granted orphan drug designation by the FDA on January 19, 2010.  On November 12, 2010, the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) issued a positive opinion on the application for orphan drug designation for tasimelteon.  A final decision on the application for orphan designation from the EMA is pending.

    On November 15, 2010, Vanda received a private letter ruling (PLR) from the Internal Revenue Service (IRS) regarding certain income tax issues associated with the availability of Vanda's net operating loss carryforwards for tax purposes. The PLR is generally consistent with Vanda's stated tax position that it is able to offset a portion of its 2010 taxable income with the company's full net operating loss carryforwards. Total net operating loss carryforwards were $123 million as of December 31, 2008. As of December 31, 2009, total net operating loss carryforwards were $156 million.  Vanda believes that the PLR received from the IRS clarifies certain tax rules regarding the use of these net operating loss carryforwards and will support Vanda's position that its December 31, 2009 net operating loss carryforwards can be fully utilized beginning in 2010.


  • General and administrative expenses are expected to be between $10.0 and $12.0 million.   This is consistent with the 2010 general and administrative expense of $10.1 million.
  • Research and development expenses are expected to be between $26.0 and $29.0 million.  This represents a $14.0 to $17.0 million increase over 2010 and reflects our investment in the Phase 3 development of tasimelteon in N24HSWD.  This is consistent with our prior guidance that we expect to spend between $30.0 and $35.0 million in total to file an NDA.
  • Total GAAP operating expenses are expected to be between $37.0 and $42.0 million.  This includes Fanapt® cost of sales of $1.5 million related to amortization of an intangible asset and $5.0 to $6.0 million of stock-based compensation.

  • CONFERENCE CALLVanda has scheduled a conference call for today, Thursday, February 10, 2011, at 10:00 AM ET.  During the call, Mihael H. Polymeropoulos, M.D., President and CEO, and James Kelly, Senior Vice President and Chief Financial Officer, will discuss quarterly results and other corporate activities.  Investors can call 1-800-591-6942 (domestic) and 1-617-614-4909 (international) prior to the 10:00 AM start time and ask for the Vanda Pharmaceuticals conference call hosted by Dr. Polymeropoulos (participant passcode 43128562).  A replay of the call will be available Thursday, February 10, 2011 at 1:00 PM ET and will be accessible until Thursday, February 17, 2011, at 5:00 PM ET.  The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers.  The access number is 66575807.

    The conference call will be broadcast simultaneously on Vanda's website,  Investors should click on the Investor Relations tab and are advised to go to the website at least 15 minutes early to register, download, and install any necessary software or presentations.  The call will also be archived on Vanda's website for a period of 30 days, through March 12, 2011.

    ABOUT VANDA PHARMACEUTICALS INC.:Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders.  For more on Vanda, please visit

    CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSVarious statements in this release are "forward-looking statements" under the securities laws. Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," and "could," and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the company's forward-looking statements include, among others: the extent and effectiveness of the development, sales and marketing and distribution support Fanapt® receives; Vanda's ability to successfully commercialize Fanapt® outside of the U.S. and Canada; delays in the completion of Vanda's clinical trials; a failure of Vanda's products to be demonstrably safe and effective; Vanda's failure to obtain regulatory approval for its products or to comply with ongoing regulatory requirements for its products; a lack of acceptance of Vanda's products in the marketplace, or a failure to become or remain profitable; Vanda's expectations regarding trends with respect to its costs and expenses; Vanda's inability to obtain the capital necessary to fund additional research and development activities; Vanda's failure to identify or obtain rights to new products; Vanda's failure to develop or obtain sales, marketing and distribution resources and expertise or to otherwise manage its growth; a loss of any of Vanda's key scientists or management personnel; losses incurred from product liability claims made against Vanda; a loss of rights to develop and commercialize Vanda's products under its license and sublicense agreements and other factors that are described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's annual report on Form 10-K for the fiscal year ended December 31, 2009 and quarterly report on Form 10-Q for the fiscal quarter ended September 30, 2010, which are on file with the SEC and available on the SEC's website at Additional information will also be set forth in those sections of Vanda's annual report on Form 10-K for the fiscal year ended December 31, 2010, which will be filed with the SEC in the first quarter of 2011. In addition to the risks described above and in Vanda's annual report on Form 10-K and quarterly reports on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

    All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

    VANDA PHARMACEUTICALS INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)Three Months EndedTwelve Months Ended(In thousands, except for per share amounts)

    December 31,
    2010December 31,
    2009December 31,

    2010December 31,
    2009Revenues:Licensing agreement





    2,569Royalty revenue511-3,141-Product sales-1,9795,2901,979Total revenues7,2634,54835,2204,548Operating expenses:Cost of sales - licensing agreement3773771,495983Cost of sales - product-1,9152,8911,915Research and development3,8222,25312,33813,874General and administrative2,7629,24510,14723,724Total operating expenses6,96113,79026,87140,496Income (loss) from operations302(9,242)8,349(35,948)Other income:Interest income142543189Grant income489-489-Total other income631592089Income (loss) before income tax provision933(9,237)9,269(35,859)Tax provision (benefit)(1,266)-2,077-Net income (loss)





    (35,859)Net income (loss) per share:Basic










    (1.33)Shares used in calculation of net income (loss) per share:Basic 28,038,07427,286,66727,916,38827,015,271Diluted28,892,34727,286,66728,534,61727,015,271VANDA PHARMACEUTICALS INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)(In thousands, except for per share amounts)

    December 31, 2010December 31, 2009ASSETSCurrent assets:Cash and cash equivalents



    205,295Marketable securities155,478-Accounts receivable5113,164Inventory-2,399Prepaid expenses, deposits and other current assets1,8432,093Deferred tax, current 1,821-Total current assets202,212212,951Property and equipment, net9371,316Restricted cash430430Intangible asset, net9,52211,017Total assets



    225,714LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable



    2,424Accrued expenses1,3242,321Accrued income taxes2,266-Deferred revenue, current 26,78926,789Total current liabilities31,02831,534Long-term liabilities:Deferred rent 490507Deferred revenue, non-current143,853170,642Total liabilities175,371202,683Stockholders' equity:Common stock2828Additional paid-in capital291,342283,836Accumulated other comprehensive income2-Accumulated deficit(253,642)(260,833)Total stockholders' equity37,73023,031Total liabilities and stockholders' equity



    225,714VANDA PHARMACEUTICALS INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)Twelve Months EndedDecember 31,December 31,(In thousands, except for per share amounts)

    20102009Cash flows from operating activities:Net income (loss)



    (35,859)Adjustments to reconcile net income (loss) to net cash usedin operating activities:Depreciation and amortization336442Stock-based compensation4,98111,230Loss on disposal of assets(23)-Amortization of premium/discounts on investments212138Amortization of intangible assets1,495983Deferred tax benefit(1,821)-Excess tax benefits from exercise of stock options(2,892)Changes in assets and liabilities:Prepaid expenses and other current assets250(805)Accounts receivable2,653(3,164)Inventory2,399(2,398)Accounts payable(1,775)1,911Accrued expenses(997)(577)Accrued income taxes3,898-Other liabilities(17)4Deferred revenue (26,789)197,431Net cash provided by (used in) operating activities(10,898)169,336Cash flows from investing activities:Acquisition of intangible asset-(12,000)Proceeds from sales of property and equipment66-Purchases of investments(202,438)(11,366)Proceeds from sales of investments-127Proceeds from maturities of investments46,75018,500Net cash used in investing activities(155,622)(4,739)Cash flows from financing activities:Excess tax benefits from exercise of stock options2,892-Proceeds from exercise of stock options8921,619Net cash provided by financing activities3,7841,619Net change in cash and cash equivalents(162,736)166,216Cash and cash equivalents, beginning of period205,29539,079Cash and cash equivalents, end of period




    SOURCE Vanda Pharmaceuticals Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Vanda Pharmaceuticals to Announce Fourth Quarter 2010 Financial Results on February 10, 2011
    2. Vanda Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 5, 2010
    3. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results
    4. Vanda Pharmaceuticals Reports Second Quarter 2009 Results
    5. Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
    6. Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
    7. Vanda Pharmaceuticals Reports First Quarter 2009 Results
    8. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
    9. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
    10. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
    11. Keryx Biopharmaceuticals to Present at 13th Annual BIO CEO and Investor Conference
    Post Your Comments:
    (Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased ... of over 5.5 million people each year. Especially those living in larger cities are ... - based in one of the most pollution-affected countries globally - decided to take ...
    (Date:10/10/2017)... ... October 10, 2017 , ... ... program has won a US2020 STEM Mentoring Award. Representatives of the FirstHand program ... in Volunteer Experience from US2020. , US2020’s mission is to change the trajectory ...
    (Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon Program Committee ... honoring scientists who have made outstanding contributions to analytical chemistry and applied ... the world’s leading conference and exposition for laboratory science, which will be held ...
    (Date:10/9/2017)... ... October 09, 2017 , ... ... in the medical journal, Epilepsia, Brain Sentinel’s SPEAC® System which uses the ... in detecting generalized tonic-clonic seizures (GTCS) using surface electromyography (sEMG). The prospective ...
    Breaking Biology Technology:
    (Date:4/11/2017)... GARDENS, Fla. , April 11, 2017 /PRNewswire/ ... management and secure authentication solutions, today announced that ... by Intelligence Advanced Research Projects Activity (IARPA) to ... IARPA,s Thor program. "Innovation has been ... and IARPA,s Thor program will allow us to ...
    (Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
    (Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
    Breaking Biology News(10 mins):